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Abstract
Introduction: Gastroparesis is a common motility disorder that is characterized by delayed gastric emptying in the
absence of mechanical obstruction. Diabetes, along with other neuromuscular and infiltrating disorders, can
predispose individuals to an increased risk of developing gastroparesis. Gastroparesis can be easily diagnosed
through gastric emptying studies but is usually difficult to successfully treat. Therapy usually begins with pro-kinetic
and anti-emetic agents.
Case presentation: Our patient was an 87-year-old African-American woman who was a nursing home resident,
with a history of diabetes mellitus type 2 and subarachnoid hemorrhage leading to aphasia, hemiplegia, seizures
and dysphagia requiring percutaneous gastric feeds. While at the nursing home, she had recurrent aspiration
pneumonia and large tube-feed residuals consistent with a diagnosis of underlying gastroparesis. Her management
included metoclopramide and reduced tube-feeding rates, which improved her symptoms. However, within
months the aspiration and increased residuals returned. After trials of different medication therapies without
success, she started mirtazapine and her residual volume and aspirations decreased with a dose of 15mg nightly.
Conclusion: In patients with gastroparesis recalcitrant to first line therapies such as metoclopramide, off-label use
of mirtazapine may provide adequate non-invasive management of gastroparetic symptoms.
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Introduction
Gastroparesis is a motility disorder involving delayed
gastric emptying with no evidence of physical obstruc-
tion [1]. It is hypothesized to affect 4 percent of the
adult population, 82 percent of who are women [2].
Patients with gastroparesis can experience symptoms of
early protracted satiety, nausea, vomiting, bloating and
abdominal pain. Gastroparesis occurs in neuromuscular
or infiltrating disorders that interfere with gastric transit.
One important association with gastroparesis is diabetes.
In patients with diabetes, the incidence of gastroparesis
is 40 percent in type 1 patients and 30 percent in type 2
patients, respectively [2,3]. In one study, gastrointestinal
disorders were present despite glycemic control and
were found in association with depression [4]. Several
studies have investigated the link between glycemic
control and the development of gastroparesis, but the
results have often been inconsistent [5]. Although gastro-
paresis seems to develop several years after the diagnosis
of diabetes and earlier in patients with poor glycemic con-
trol, the gastrointestinal symptoms observed are similar in
patients who are non-diabetic. Gastric emptying scintig-
raphy is the gold standard for diagnosis of gastroparesis
and consists of measuring the transit time of a radiola-
beled solid meal. If greater than 10 percent of the meal
remains four hours after ingestion, then there is gastropar-
esis [2]. Studies such as a wireless motility capsule and
stable isotope breath test may also be used for diagnosis,
and employ measurement of the capsule passage from the
stomach to the duodenum or the breakdown of labeled
medium-chain triglycerides, respectively [3]. Gastrointes-
tinal transit may also be assessed simply by using serial
abdominal radiographs and measuring radiolabeled stool
output [6].* Correspondence: gooden.janelle@mayo.edu
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Treatment of gastroparesis can be very challenging for
those patients who have it. Therapy usually begins with
correction of underlying electrolyte abnormalities and en-
hanced glucose control in diabetics, as it has been shown
that hyperglycemia slows gastric emptying [7]. Medication
management usually includes an anti-emetic agent for
symptom control, in combination with a pro-kinetic agent
to stimulate movement. The underlying pathophysiology
involves enhancing neurotransmitters, primarily dopamine,
motilin and serotonin [2]. Common agents that work on
the dopaminergic neurotransmitters include phenothiazine,
metoclopramide, and domperidone. Unfortunately, there
are numerous side effects including drowsiness, extrapyr-
amidal symptoms, xerostomia and rash. Erythromycin and
low dose tricyclic antidepressants have also been employed
with some success, but erythromycin commonly causes
diarrhea and tricyclics may cause anti-cholinergic effects
that enhance symptoms. More invasive management stra-
tegies include implantation of a gastric electric stimulator,
which has been shown to improve nausea and vomiting
within six weeks of therapy, and botulinum toxin injection
is continually being investigated for efficacy [8,9]. Despite
these options, there remains a clear need to look at other
potential medications for gastroparesis.
Case presentation
An 87-year-old African-American woman who was a
nursing home resident with a history of diabetes mellitus
type 2 came to the attention of medical staff because of
continued high post-feed residuals from her tube feed-
ings. She was aphasic and could not give a direct history
to the staff. Her pertinent medical history included
diabetes diagnosed nine years previously, subarachnoid
hemorrhage leading to her aphasia, hemiplegia, seizures
and dysphagia requiring percutaneous gastric feeds. She
was completely dependent upon the tube feedings for
nutritional and hydration support. She was noted to
have recurrent monthly episodes of aspiration pneumo-
nia, abdominal bloating, vomiting and large tube-feed
residuals consistent with a diagnosis of underlying gas-
troparesis. With her ongoing decline, our patient was in
a palliative state, desiring comfort measures with a limi-
tation on testing. As a result, gastric emptying studies
were not undertaken. On examination, she was aphasic
with a percutaneous gastric tube in place and residuals
of greater than 150mL. Her medications included allo-
purinol, buspirone, calcium and vitamin D, citalopram,
insulin, levetiracetam, furosemide, levothyroxine, meto-
prolol, mexiletine, amlodipine, omeprazole, gabapentin
and a prednisone taper for bullous pemphigoid. Labora-
tory studies showed no abnormalities and an abdominal
X-ray showed no evidence of mechanical obstruction.
She was started on a course of metoclopramide 30mg
for pro-kinetic effect and prochlorperazine 25mg daily
for nausea. Both medications provided temporary im-
provement in nausea and vomiting and modest reduc-
tions in her residuals.
Her nursing home course was complicated by continued
episodes of recurrent aspiration pneumonia requiring hos-
pitalization and oxygen supplementation. The doses of
her anti-emetic and pro-kinetic agents were adjusted and
her tube feeds were slowed significantly. There were con-
siderable risks to our patient as the staff continued to slow
the tube feeds, which placed her at risk for low nutritional
intake. Despite the changes, within a couple months, her
increased post-void residuals returned. Her clinical picture
and family wishes precluded invasive therapies such as a
gastric electric stimulator and botulinum injections. Tri-
cyclics and erythromycin were not considered ideal with
her underlying mental and neurologic disorders and medi-
cation regimen. After review of the literature for non-
invasive therapies to manage recalcitrant gastroparesis,
two reports of success with mirtazapine were found. One
case report involved a patient with post-gastropexy-
related recalcitrant gastroparesis that promptly resolved
with mirtazapine [10]. In another report, a 27-year-old
woman with diabetes type 1 and gastroparesis recalcitrant
to seven months of therapy with all known medication
regimen and botulinum toxin injections, had resolution of
her symptoms within one week of therapy with 15mg of
mirtazapine [11].
Our patient’s residual volume decreased from greater
than 170mL to less than 70mL and she had no aspira-
tion pneumonia for months prior to her death. Efficacy
was noted at a threshold dose of 15mg nightly.
Discussion
Gastroparesis can be a challenging and life-threatening
complication of diabetes mellitus. In our patient, gastro-
paresis contributed to recurrent aspiration pneumonias in
a debilitated nursing home resident and was likely second-
ary to long-standing diabetes as there is an incidence of
up to 50 percent in such patients [12]. We used the first-
line therapies of metoclopramide and prochlorperazine at
varying doses to no lasting avail. Our patient was not an
ideal candidate for erythromycin, tricyclics or invasive
management. Mirtazapine provided improvement in her
post-feeding residuals and reduced her aspiration events.
Mirtazapine is a serotonergic 5-hydroxytryptamine 2/3
(5HT2/3) receptor antagonist and noradrenergic anti-
depressant [13], which has been used off-label for man-
agement of gastroparesis in the cases as described. Its
exact mechanism of action for gastroparesis is unclear but
thought related to serotonergic and noradrenergic effects.
Its effects on relieving gastroparesis are thought to be
related to potent 5-HT3 antagonism and has been
reported effective in relieving post-operative and recalci-
trant severe gastroparesis [10,11], however, there is very
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little evidence to support or standardize this off-label use.
There have been no randomized control trials for further
investigation although mirtazapine is an attractive alterna-
tive non-invasive regimen with minimal side effects and
favorable efficacy. It also has the additional benefit of
being an antidepressant. It is worthwhile to employ this
therapy when other primary therapies have failed. Mirta-
zapine is especially helpful for patients in whom invasive
interventions are impractical, including patients who are
older, desire non-invasive care or have multiple comorbid-
ities that preclude procedures. The use of mirtazapine has
never been reported with regards to reduced tube-feed
residuals.
Conclusion
This report presents the case of an older African-
American woman with long-standing diabetes who
developed gastroparesis after a debilitating cerebrovascu-
lar accident. Her symptoms were temporarily managed
with conventional anti-emetic and pro-kinetic therapies
but later became persistent until the initiation of mirta-
zapine. In patients with gastroparesis that is recalcitrant
to first-line therapies, or where invasive therapies are
impractical, off-label use of mirtazapine may provide
non-invasive management of persistent gastroparetic
symptoms. The mechanism of its effect on gastroparesis
has not been clearly elucidated or studied, and there has
been only one non-surgical case previously reported in
the literature.
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